Polymorph Screening
Predict crystal polymorphs and assess pharmaceutical stability to guide solid-state form selection.
Polymorph Screening
Polymorphism -- the ability of a molecule to crystallize in more than one crystal form -- has profound implications for drug development. Different polymorphs can exhibit different solubility, dissolution rates, bioavailability, and stability profiles. This workflow uses computational crystal structure prediction and PXRD analysis to map the polymorph landscape before committing to costly experimental screening.
Overview
Over 80% of pharmaceutical molecules exhibit polymorphism. Selecting the wrong crystal form can lead to process failures, patent vulnerabilities, and even product recalls (as in the well-known case of ritonavir Form II). XtalNet uses AI-driven crystallography to predict plausible crystal structures and rank them by lattice energy and pharmaceutical relevance. OpXRD analyzes powder X-ray diffraction patterns to identify and characterize crystal phases. Together, they enable rational solid-state form selection early in development.
Tool Chain
- XtalNet -- AI-driven crystal structure prediction and polymorph ranking
- OpXRD -- Powder X-ray diffraction pattern analysis and phase identification
Prerequisites
- SMILES string or molecular formula for the compound of interest
- Experimental PXRD data (if available) in CSV or XY format
- Understanding of basic crystallography concepts (unit cell, space group, lattice energy)
Step-by-Step Guide
Predict the polymorph landscape
Submit the compound SMILES to XtalNet for crystal structure prediction. The algorithm generates multiple candidate crystal packings by exploring different space groups, conformational states, and packing motifs. Each candidate is scored by predicted lattice energy (more negative values indicate greater thermodynamic stability) and ranked by pharmaceutical relevance considering hydrogen bonding networks, packing density, and void volume.
Analyze predicted crystal structures
Review the top-ranked crystal structure predictions. For each polymorph candidate, examine the unit cell parameters (a, b, c, alpha, beta, gamma), space group assignment, molecular conformation within the lattice, and hydrogen bonding network. Compare the predicted density across polymorphs -- higher density generally correlates with greater thermodynamic stability. Identify polymorphs with distinct packing motifs (layer structures versus channel structures versus close-packed) as these are most likely to represent genuinely different forms.
Simulate PXRD patterns
Generate simulated PXRD patterns for each predicted polymorph. These computed diffraction fingerprints serve as references for experimental identification. Compare the patterns to verify that predicted polymorphs are distinguishable by standard laboratory PXRD equipment (peaks separated by at least 0.2 degrees 2-theta at typical resolution).
Match against experimental data (if available)
If you have experimental PXRD data from crystallization trials, submit it to OpXRD for phase identification and refinement. OpXRD matches observed peaks against predicted patterns and reference databases to determine which polymorph form is present, whether the sample contains a single phase or a mixture, and the degree of crystallinity. Amorphous halos indicate incomplete crystallization.
Assess pharmaceutical properties
For the identified polymorph candidates, evaluate pharmaceutical-relevant properties. Polymorphs with extensive hydrogen bonding networks tend to have lower solubility but higher stability. Polymorphs with channel structures may accommodate solvent molecules (solvates/hydrates) that complicate manufacturing. Compare predicted dissolution behavior across forms to identify the polymorph offering the best balance of solubility and stability for your dosage form.
Document and recommend
Compile a polymorph assessment report listing all identified forms with their structural characteristics, stability rankings, and pharmaceutical property predictions. Recommend the preferred polymorph for development based on thermodynamic stability (to avoid form conversions during manufacturing and storage), adequate solubility for the target dose and formulation, and freedom to operate in the patent landscape.
Expected Outputs
- Ranked list of predicted polymorph candidates with lattice energies
- Crystal structure visualizations with unit cell parameters and space groups
- Simulated and matched PXRD patterns for each form
- Hydrogen bonding network analysis and packing motif classification
- Pharmaceutical property assessment (stability, solubility, dissolution ranking)
- Polymorph selection recommendation report
Tips and Best Practices
- Always screen for polymorphs before selecting a crystallization process. Discovering a more stable form late in development can invalidate months of formulation work.
- Use high-resolution PXRD data (step size 0.02 degrees or finer) for best matching accuracy with OpXRD.
- Consider the kinetic versus thermodynamic stability distinction. The most thermodynamically stable polymorph is safest for development, but metastable forms may offer solubility advantages if conversion kinetics are slow enough.
- For compounds with known conformational flexibility (multiple rotatable bonds), expect more polymorph candidates. Rigid molecules tend to have fewer forms.
- Document all observed polymorphs for patent filings, even forms that are not selected for development. Polymorph patents provide valuable IP protection.
- Cross-reference predicted forms against the Cambridge Structural Database (CSD) if related structures have been reported in the literature.
Was this page helpful?